Want to see PHR full AI Analyst Report?
Top Page
Phreesia
(NYSE:PHR)
Select Model
Select Model
Rating:66Neutral
Price Target:
$11.50
▲(25.41% Upside)
Action:Reiterated
Date:06/25/26
The score is driven primarily by improving fundamentals—especially strong operating and free cash flow and a shift to profitability—reinforced by maintained guidance and EBITDA expansion signals from the latest earnings call. Offsetting this, the stock’s technical setup remains weak (below major moving averages with negative MACD) and valuation is stretched (P/E ~60), increasing sensitivity to any slowdown or execution missteps.
Positive Factors
Strong cash generation and FCF growth
Phreesia has converted improving earnings into cash with high-quality free cash flow growth (~19% TTM) and FCF equal to ~86% of net income. Sustained cash generation supports reinvestment, M&A funding, debt service and resilience through cyclical healthcare spending shifts.
Negative Factors
Sequential subscription revenue decline
A sequential contraction in subscription revenue signals vulnerability in core recurring provider fees, which can pressure lifetime value and renewal economics. If subscription uptake or pricing moderation persists, it could restrain durable revenue growth and make earnings more dependent on non-subscription streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation and FCF growth
Phreesia has converted improving earnings into cash with high-quality free cash flow growth (~19% TTM) and FCF equal to ~86% of net income. Sustained cash generation supports reinvestment, M&A funding, debt service and resilience through cyclical healthcare spending shifts.
Read all positive factors
Phreesia Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue by different business areas, revealing which segments are driving growth and where strategic focus may be needed.
Breaks down revenue by different business areas, revealing which segments are driving growth and where strategic focus may be needed.
Data provided by:
The Fly
The FlyPhreesia (PHR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$662.62M
Dividend YieldN/A
Average Volume (3M)1.40M
Price to Earnings (P/E)70.0
Beta (1Y)1.01
Revenue Growth14.05%
EPS GrowthN/A
CountryUS
Employees2,082
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.15
Shares Outstanding61,811,890
10 Day Avg. Volume1,030,953
30 Day Avg. Volume1,395,591
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda14.04
Forecast
1Y Price Target
$13.83Price Target Upside50.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)0.4
Revenue Forecast (FY)$515.19M
Phreesia Business Overview & Revenue Model
Company Description
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake p...
How the Company Makes Money
Phreesia generates revenue primarily through (1) subscription/usage-based fees paid by healthcare providers for access to and use of its software platform and related modules, and (2) fees from life sciences companies for marketing and patient eng...
Phreesia Earnings Call Summary
Earnings Call Date:May 27, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Sep 09, 2026
Earnings Call Sentiment Positive
The call presented multiple clear operating and financial positives: solid top-line growth (+13% YoY), strong adjusted EBITDA improvement (+~46% YoY) and a return to net income, improved operating and free cash flow, enhanced liquidity via refinancing and a larger securitization facility for Access One, and maintained full-year guidance. Headwinds included a sequential decline in subscription revenue, higher variability and lower-than-expected client commitments in Network Solutions for the back half of the year, and some dependence of Payment Solutions growth on the recent Access One acquisition. On balance, the positive operational and financial momentum, maintaining guidance, and strategic financing and product initiatives outweigh the listed challenges.Positive Updates
Revenue Growth
Total revenue for Q1 FY2027 was $130.9 million, up 13% year-over-year.
Negative Updates
Subscription Revenue Sequential Decline
Subscription revenue declined approximately 6% sequentially in Q1; management attributed some of the year-over-year subscription comps to a nonrecurring related services contribution in the prior year and noted deliberate moderation of subscription pricing to preserve retention and downstream monetization.
Read all updates
Q1-2027 Updates
Positive
Negative
Revenue Growth
Total revenue for Q1 FY2027 was $130.9 million, up 13% year-over-year.
Read all positive updates
Company Guidance
Phreesia reiterated its fiscal 2027 guidance: revenue of $510–$520 million (assuming ~ $37M contribution from Access One and no further M&A) and adjusted EBITDA of $125–$135 million, while reiterating mid‑single‑digit AHSC growth and low‑single‑digit total revenue per AHSC growth for the year; Q1 results supporting that outlook included revenue of $130.9M (+13% YoY), Payment Solutions growth of 40% and Network Solutions growth of 15%, adjusted EBITDA of $30.5M (23% margin), net income of $3.0M (third consecutive positive quarter), total managed payments of $1.786B and a Payment Solutions revenue rate of 2.3%; balance sheet and cash highlights: cash and equivalents $76.4M, $84M drawn on a new $275M senior secured revolver (repayment of prior bridge used $92M), PNC securitization facility increased to $300M, net cash from operations $23.9M and free cash flow $16.4M, and management said a May restructuring will generate meaningful annualized run‑rate expense savings.Phreesia Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
72
Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 495.59M | 480.59M | 419.81M | 356.30M | 280.91M | 213.23M |
| Gross Profit | 326.13M | 326.47M | 284.88M | 232.29M | 171.64M | 131.84M |
| EBITDA | 42.42M | 29.47M | -25.58M | -102.94M | -145.48M | -92.30M |
| Net Income | 9.18M | 2.31M | -58.53M | -136.88M | -176.15M | -118.16M |
Balance Sheet | ||||||
| Total Assets | 666.14M | 663.79M | 388.42M | 370.33M | 370.06M | 494.48M |
| Cash, Cash Equivalents and Short-Term Investments | 74.71M | 73.83M | 84.22M | 87.52M | 176.68M | 313.81M |
| Total Debt | 92.56M | 102.45M | 17.80M | 11.98M | 9.18M | 15.80M |
| Total Liabilities | 307.05M | 326.58M | 123.61M | 118.88M | 82.24M | 77.20M |
| Stockholders Equity | 359.09M | 337.21M | 264.81M | 251.45M | 287.82M | 417.28M |
Cash Flow | ||||||
| Free Cash Flow | 72.74M | 67.71M | 8.29M | -57.48M | -116.33M | -105.52M |
| Operating Cash Flow | 87.89M | 78.81M | 32.38M | -32.38M | -90.12M | -74.71M |
| Investing Cash Flow | -149.69M | -161.88M | -24.09M | -39.67M | -26.20M | -65.23M |
| Financing Cash Flow | 47.60M | 72.85M | -11.49M | -17.11M | -20.80M | 234.97M |
Phreesia Technical Analysis
Positive
9.17
Price Trends
9.63
Positive
10.13
Positive
14.60
Negative
Market Momentum
0.39
Negative
60.43
Neutral
64.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHR, the sentiment is Positive. The current price of 9.17 is below the 20-day moving average (MA) of 9.94, below the 50-day MA of 9.63, and below the 200-day MA of 14.60, indicating a neutral trend. The MACD of 0.39 indicates Negative momentum. The RSI at 60.43 is Neutral, neither overbought nor oversold. The STOCH value of 64.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHR.
Phreesia Risk Analysis
Phreesia disclosed 57 risk factors in its most recent earnings report. Phreesia reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Phreesia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $999.09M | 50.51 | 3.31% | ― | -1.19% | -21.87% | |
66 Neutral | $662.62M | 69.97 | 2.79% | ― | 14.05% | ― | |
61 Neutral | $1.68B | -9.58 | -12.37% | ― | -1.50% | 83.75% | |
61 Neutral | $5.42B | -249.80 | -2.86% | ― | 2.26% | 86.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | ― | ― | ― | ― | ― | ― | |
56 Neutral | $1.23B | -11.64 | -30.85% | ― | 10.59% | 46.79% |
* Healthcare Sector Average
PHR
Phreesia
10.72
-16.88
-61.16%
PINC
―
―
―
―
TDOC
Teladoc
9.28
1.01
12.21%
TXG
10x Genomics
42.73
30.26
242.66%
SDGR
Schrodinger
16.49
-4.65
-22.00%
GDRX
GoodRx Holdings
2.95
-1.88
-38.92%
Phreesia Corporate Events
Executive/Board ChangesShareholder Meetings
Phreesia Shareholders Back Leadership, Governance at Annual Meeting
Positive
Jun 24, 2026
On June 24, 2026, Phreesia, Inc. held its annual meeting of stockholders, where shareholders elected Chaim Indig and Jon Kessler as Class I directors to serve three-year terms ending at the 2029 annual meeting, reinforcing continuity in the compan...
Business Operations and Strategy
Phreesia Announces Workforce Restructuring to Cut Operating Costs
Negative
May 11, 2026
On May 7, 2026, Phreesia, Inc. implemented a restructuring plan aimed at reducing operating expenses and aligning its cost structure with current business priorities, including the elimination of about 220 positions, roughly half of which are cont...
Business Operations and StrategyPrivate Placements and Financing
Phreesia Expands Receivables Facility and Guarantees Obligations
Positive
May 4, 2026
On April 30, 2026, Phreesia’s indirect subsidiaries AccessOne Funding and AccessOne MedCard amended their existing receivables purchase facility with PNC Bank, increasing the facility limit from $200 million to $300 million and extending its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.